Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company`s lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia`s Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Website: cel-sci.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 20.0% (LTM)

Entry Point: Share price is 736.4% higher than minimum and 87.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: CVM
Share price, USD:  (-7.0%)1.6
year average price 6.3138  


year start price 5.1100 2025-05-20

max close price 13.0400 2025-08-27

min close price 1.1900 2026-05-13

current price 1.6000 2026-05-19
Common stocks: 84 540 132

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 135
Net Debt ($m): -33
EV (Enterprise Value): 102
Price to Book: 9.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-08-30globenewswire.com

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

2023-07-18InvestorPlace

Why Is CEL-SCI (CVM) Stock Down 23% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 4M 959 009 970 102 4M 983 208 988 762 1M 4M 0 0 0 4M 499 000
grossProfit -4M -959 009 -970 102 -4M -983 208 -988 762 -1M -4M 0 0 0 -4M -499 000
researchAndDevelopmentExpenses 16M 4M 4M 18M 5M 5M 4M 22M 6M 6M 5M 25M 23M
generalAndAdministrativeExpenses 0 2M 2M 8M 2M 2M 2M 9M 2M 2M 2M 11M 13M
sellingAndMarketingExpenses 0 0 0 0 0 -988 762 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 2M 1M 4M 2M 1M 2M 9M 2M 2M 2M 11M 13M
otherExpenses 0 -959 009 0 0 0 13 758 -25 941 -22M -3854 -7500 -50 171 76 355 2M
operatingExpenses 21M 5M 5M 22M 7M 6M 6M 31M 8M 8M 8M 36M 36M
costAndExpenses 25M 5M 6M 26M 7M 7M 6M 31M 8M 8M 8M 36M 36M
netInterestIncome -648 944 -745 673 -674 741 -1M -1M
interestIncome 0 0 0 0 0 0 0 675.416 0 0 0 1081.034 1125.288
interestExpense 648 944 172 050 178 286 745 673 190 705 182 701 197 696 675 416 181 670 159 063 152 789 1M 1M
depreciationAndAmortization 4M 959 009 970 102 4M 984 208 988 762 1M 4M 985 699 977 939 938 372 4M 499 000
ebitda -21M -5M -5M -22M -6M -6M -6M -28M -7M -7M -7M -32M -35M
ebit -25M -26M -32M -36M -35M
nonOperatingIncomeExcludingInterest -47 620 -177 680 42 810 -443 148 -982 120
operatingIncome -25M -5M -6M -26M -7M -7M -6M -31M -8M -8M -8M -36M -36M
totalOtherIncomeExpensesNet -601 319 -175 821 -178 286 -567 991 -186 323 -168 943 -25 941 -718 228 -3854 -166 563 -374 512 -637 888 -166 980
incomeBeforeTax -25M -6M -7M -27M -7M -7M -7M -32M -8M -8M -8M -37M -36M
incomeTaxExpense 0 0 0 0 0 -2 171 755 0 177 816 166 563 374 512 2M 3M
netIncomeFromContinuingOperations -25M -27M -32M -38M -37M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 -171 553 929 122 350 861
netIncome -25M -6M -7M -27M -7M -7M -7M -32M -8M -9M -8M -38M -39M
netIncomeDeductions 0 659 456 171 552 929 122 350 861
bottomLineNetIncome -25M -28M -32M -38M -37M
eps -6.27 -1.36 -2.33 -13.5 -0.14 -0.14 -0.14 -21.9 -0.19 -0.2 -0.19 -26.7 -28.8
epsDiluted -6.27 -13.5 -21.9 -26.7 -28.8
weightedAverageShsOut 4M 4M 3M 2M 54M 52M 48M 1M 44M 44M 43M 1M 1M
weightedAverageShsOutDil 4M 4M 3M 2M 54M 52M 48M 1M 44M 44M 44M 1M 1M
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
grossProfitRatio 0 0 0 0 0 0 0 0
ebitdaratio 0 0 0 0 0 0 0 0
operatingIncomeRatio 0 0 0 0 0 0 0 0
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0
netIncomeRatio 0 0 0 0 0 0 0 0
epsdiluted -1.36 -2.33 -0.14 -0.14 -0.14 -0.19 -0.2 -0.19
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
cashAndCashEquivalents 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 36M
shortTermInvestments 0 7500 0 0 0 16 129 16.129 0 0 0 0 0 6M
cashAndShortTermInvestments 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 42M
netReceivables 0 0 0 0 0 0 -2M 0 -2M -2M -2M 0 54 922
accountsReceivables 0 0 0 0 54 922
otherReceivables 0 0 0 0 0
inventory 0 518 040 882 692 1M 3M 2M 2M 2M 2M 2M 2M 2M 2M
prepaids 0 294 097 520 368 762 063 998 482
otherCurrentAssets 643M 311 633 215 962 3500 602 466 696 648 3M 4245 3M 3M 2M 0 0
totalCurrentAssets 11 596M 3M 3M 6M 4M 9M 6M 7M 8M 13M 20M 25M 45M
propertyPlantEquipmentNet 12 902M 14M 15M 17M 18M 19M 20M 21M 22M 23M 24M 25M 28M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 119 856 130 585 141 263 165 492 173 028 180 482 188 294 197 704 183 074 192 231 202 070 212 201 275 866
goodwillAndIntangibleAssets 119 856 130 585 141 263 165 492 173 028 180 482 188 294 197 704 183 074 192 231 202 070 212 201 275 866
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3 657M 4M 4M 4M 2M 2M 2M 2M 2M 2M 104 607 164 299 2M
totalNonCurrentAssets 16 560M 18M 19M 21M 21M 22M 23M 24M 25M 26M 24M 25M 31M
otherAssets 0 0 0 0 0 0 -0 0 0 0 0 0 0
totalAssets 28 156M 20M 22M 27M 24M 30M 29M 31M 32M 38M 45M 51M 76M
totalPayables 1M 1M 2M 2M 2M
accountPayables 1M 2M 2M 1M 1M 1M 1M 2M 2M 2M 2M 2M 2M
otherPayables 0 0 0 0 0
accruedExpenses 0 566 042 2M 842 492 859 216
shortTermDebt 2 441M 2M 5M 2M 4M 2M 2M 0 2M 2M 2M 0 0
capitalLeaseObligationsCurrent 0 2M 2M 2M 698 665
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 1 0 0 0 0 0 0 1M
otherCurrentLiabilities 2 689M 2M -895 794 -2M -199 628 2M 2M 0 2M 2M 1M 471 488 -421 836
totalCurrentLiabilities 5 131M 6M 5M 5M 6M 5M 5M 6M 5M 5M 5M 5M 4M
longTermDebt 6 943M 8M 8M 0 10M 11M 11M 0 12M 13M 13M 0 0
capitalLeaseObligationsNonCurrent 7M 9M 12M 14M 15M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 125M 125 000 125 000 125 000 125 000 124 999 125 000 125 000 125 000 125 000 125 000 125 000 125 000
totalNonCurrentLiabilities 7 068M 8M 8M 10M 10M 11M 11M 12M 12M 13M 13M 14M 15M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 7M 10M 11M 12M 12M 13M 13M 14M 14M 14M 15M 15M 16M
totalLiabilities 12 199M 13M 14M 14M 16M 16M 16M 17M 18M 18M 18M 18M 19M
treasuryStock 0 0 0 0 0
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 80 157 53 214 843 496 637 870 542 578 540 837 500 186 474 223 447 484 437 878 437 256 434 484 432 072
retainedEarnings -539M -533M -528M -514M -508M -501M -494M -487M -479M -471M -463M -455M -418M
additionalPaidInCapital 555M 526M 500M 487M 474M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0
totalStockholdersEquity 16M 7M 8M 13M 8M 14M 13M 13M 15M 20M 27M 32M 57M
totalEquity 15 957M 7M 8M 13M 8M 14M 13M 13M 15M 20M 27M 32M 57M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 28 156M 20M 22M 27M 24M 30M 29M 31M 32M 38M 45M 51M 76M
totalInvestments 0 7500 0 0 51 129 16 129 16.129 0 0 0 0 0 6M
totalDebt 9 384M 10M 11M 12M 12M 13M 13M 14M 14M 14M 15M 15M 16M
netDebt -1 570M 8M 9M 7M 12M 7M 10M 9M 9M 4M -3M -7M -20M
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
othertotalStockholdersEquity 540M 535M 516M 515M 506M 494M 491M 489M
totalLiabilitiesAndStockholdersEquity 20M 22M 24M 30M 29M 32M 38M 45M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2025 q1 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q3
date 2025-09-30 2025-06-30 2025-03-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-09-30
symbol CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM CVM
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363 725 363
filingDate 2025-12-29 2025-01-13 2023-12-21 2022-12-27 2021-12-21
acceptedDate 2025-12-23 17:36:36 2025-08-14 09:31:38 2025-05-14 16:20:57 2025-01-13 16:16:33 2024-08-14 16:27:32 2024-05-15 16:17:31 2024-02-14 16:31:12 2023-12-21 16:15:39 2023-08-10 16:10:28 2023-05-12 16:11:55 2023-02-14 16:16:36 2022-12-27 16:15:57 2021-12-21 16:33:58
fiscalYear 2025 2024 2023 2022 2021
period FY Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY FY
netIncome -25 411M -6M -7M -27M -7M -7M -7M -32M -8M -8M -8M -37M -36M
depreciationAndAmortization 3 885M 959 009 970 102 4M 984 208 988 762 1M 4M 985 699 985 439 988 543 4M 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 0 0 713 624
stockBasedCompensation 1 911M 207 288 849 645 4M 1M 2M 2M 7M 2M 2M 2M 12M 14M
changeInWorkingCapital 1M 557 033 32 954 -1M 273 457 -88 962 -836 743 -2M -68 521 -2M 301 372 3M -483 474
accountsReceivables 0 0 0 0 0 0 0 444 780 0 0 0 54 922 497 077
inventory 973 665 416 649 12 340 -172 608 -64 030 -141 302 -98 765 -156 727 -194 925 -42 253 212 687 -159 430 -1M
accountsPayables -442 710 -101 765 -369 305 -460 576 304 569 -131 861 -765 078 257 845 -36 225 218 126 -115 285 374 890 445 981
otherWorkingCapital 631 460 242 149 389 919 -579 007 32 918 184 201 27 100 -2M 162 629 -2M 203 970 2M -240 000
otherNonCashItems 2 494M 1712 350 109 1M 35 625 4M 2504 15 293 3243 -144 391 153 936 480 117 1M
netCashProvidedByOperatingActivities -17 120M -4M -4M -19M -5M -5M -5M -23M -6M -7M -5M -18M -19M
investmentsInPropertyPlantAndEquipment -38M 0 0 -94 875 -23 472 0 -64 861 -361 892 -196 860 -111 452 -53 580 -660 633 -9M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 -6M
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 6M 0
otherInvestingActivities 0 -13 211 -10 370 6129.259 -6168.405
netCashProvidedByInvestingActivities -38M -108 086 -372 262 5M -15M
netDebtIssuance -2M -2M -2M -600 041 534 154
longTermNetDebtIssuance -2M -2M -2M -600 041 534 154
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 25M 24M 7M 0 48M
netCommonStockIssuance 25M 24M 7M 0 48M
commonStockIssuance 25M 24M 7M -38 385 48M
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0
netPreferredStockIssuance 0 0 -297 622 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 23 350M -2M -297 622 -38 385 6M
netCashProvidedByFinancingActivities 23 373M 20M 5M -638 426 55M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 6 215M -131 449 -3M 592 438 -5M 2M -904 295 -19M -5M -8M -5M -13M 21M
cashAtEndOfPeriod 10 953M 2M 2M 5M 384 652 5M 3M 4M 5M 10M 18M 23M 36M
cashAtBeginningOfPeriod 4 738M 2M 5M 4M 5M 3M 4M 23M 10M 18M 23M 36M 16M
operatingCashFlow -17 120M -4M -4M -19M -5M -5M -5M -23M -6M -7M -5M -18M -19M
capitalExpenditure -38M 0 0 -94 875 -23 477 0 -64 861 -372 262 -196 860 -111 452 -53 580 -660 633 -9M
freeCashFlow -17 158M -4M -4M -19M -5M -5M -5M -23M -6M -8M -5M -19M -28M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0
fillingDate 2025-08-14 2025-05-14 2024-08-14 2024-05-15 2024-02-14 2023-08-10 2023-05-12 2023-02-14
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023
otherInvestingActivites 0 0 0 0 -13.211 0 0 0
netCashUsedForInvestingActivites 0 0 -23 472 0 -64 861 -196 860 -111 452 -53 580
debtRepayment -510 346 -498 860 -448 283 -440 415 -426 593 -396 148 -388 352 -372 871
commonStockIssued 5M 3M 45 360 8M 5M 0 0 -9010
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites -681 441 -381 371 125 980 -714 024 -504 913 1M 0 447 291
netCashUsedProvidedByFinancingActivities 4M 2M -322 303 7M 4M 951 563 -388 352 65 410
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2026-02-18 ET
CEL-SCI Reports Fiscal First Quarter 2026 Results
2025-12-29 ET
CEL-SCI Reports Fiscal 2025 Results
2025-10-20 ET
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
2025-10-10 ET
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
2025-08-29 ET
CEL-SCI Announces Closing of $10 Million Public Offering
2025-08-27 ET
CEL-SCI Announces Pricing of $10 Million Public Offering
2025-08-27 ET
CEL-SCI Announces Proposed Public Offering
2025-08-14 ET
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
2025-08-13 ET
CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
2025-07-14 ET
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
2025-07-11 ET
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
2025-07-11 ET
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
2025-06-18 ET
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
2025-05-23 ET
CEL-SCI Announces Closing of Public Offering
2025-05-21 ET
CEL-SCI Announces Pricing of Public Offering
2025-05-21 ET
CEL-SCI Announces Proposed Public Offering
2025-05-21 ET
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
2025-05-19 ET
CEL-SCI Announces Combination of Common Stock
2025-05-15 ET
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
2025-04-23 ET
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
2025-04-08 ET
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
2025-03-24 ET
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
2025-03-18 ET
CEL-SCI Announces Closing of $2.5 Million Offering
2025-03-17 ET
CEL-SCI Announces Pricing of $2.5 Million Offering
2025-03-17 ET
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
2025-03-14 ET
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
2025-02-20 ET
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
2025-02-18 ET
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
2025-01-14 ET
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
2024-12-31 ET
CEL-SCI Announces Closing of $5 Million Offering
2024-12-29 ET
CEL-SCI Announces Pricing of $5 Million Public Offering
2024-12-27 ET
CEL-SCI Announces Proposed Public Offering of Common Stock
2024-12-12 ET
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
2024-11-07 ET
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
2024-10-22 ET
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
2024-10-01 ET
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
2024-09-16 ET
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
2024-09-10 ET
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
2024-09-04 ET
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
2024-08-15 12:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
2024-07-29 20:05 ET
CEL-SCI Announces Closing of $10.8 Million Offering
2024-07-26 15:52 ET
CEL-SCI Announces Pricing of $10.8 Million Offering
2024-07-26 12:23 ET
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
2024-07-08 13:15 ET
CEL-SCI Appoints Robert Watson as Chairperson of the Board
2024-06-18 12:00 ET
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
2024-06-06 11:00 ET
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
2024-05-16 13:00 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
2024-05-08 13:00 ET
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
2024-04-23 13:00 ET
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
2024-03-19 13:00 ET
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
2024-03-19 13:00 ET
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
2024-03-06 13:45 ET
CEL-SCI Corporation Issues Letter to Shareholders
2024-02-15 13:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
2024-02-13 17:00 ET
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
2024-02-13 17:00 ET
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
2024-02-09 13:30 ET
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
2024-02-09 13:30 ET
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
2024-02-06 14:00 ET
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
2024-01-31 14:00 ET
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
2023-12-22 13:00 ET
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
2023-12-04 13:30 ET
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
2023-11-20 21:15 ET
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
2023-11-20 ET
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
2023-11-16 13:30 ET
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
2023-11-16 ET
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
2023-10-30 13:20 ET
CEL-SCI Issues Letter to Shareholders
2023-10-24 12:00 ET
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
2023-10-23 13:15 ET
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
2023-10-19 12:00 ET
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
2023-10-05 12:45 ET
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
2023-09-26 13:00 ET
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
2023-08-11 12:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
2023-07-20 15:36 ET
CEL-SCI Announces Closing of Public Offering
2023-07-18 01:23 ET
CEL-SCI Announces Pricing of Public Offering
2023-07-17 20:05 ET
CEL-SCI Announces Proposed Public Offering of Common Stock
2023-07-14 13:15 ET
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
2023-07-11 12:45 ET
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
2023-06-22 14:19 ET
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
2023-05-15 13:00 ET
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
2023-05-12 20:30 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
2023-04-28 01:12 ET
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
2023-04-27 ET
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
2023-04-19 13:00 ET
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
2023-03-08 14:00 ET
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
2023-03-03 14:00 ET
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
2023-02-15 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
2022-12-28 14:00 ET
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
2022-11-22 14:00 ET
CEL-SCI Corporation Issues Letter to Shareholders
2022-10-17 12:50 ET
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
2022-09-12 13:00 ET
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
2022-09-12 ET
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
2022-09-07 12:45 ET
CEL-SCI Corporation Issues Letter to Shareholders
2022-08-19 12:45 ET
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
2022-08-15 13:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
2022-08-08 12:45 ET
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
2022-07-14 14:00 ET
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
2022-06-08 13:00 ET
CEL-SCI Corporation to Present at LD Micro Invitational
2022-06-07 11:30 ET
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
2022-05-27 13:00 ET
CEL-SCI Announces Publication of ASCO 2022 Abstracts
2022-05-16 12:50 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
2022-04-22 13:21 ET
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
2022-02-14 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
2021-12-22 14:00 ET
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
2021-10-22 12:00 ET
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
2021-08-16 13:00 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
2021-07-07 12:00 ET
CEL-SCI Corporation Issues Letter to Shareholders
2021-07-02 15:20 ET
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
2021-06-30 13:00 ET
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
2021-06-28 13:20 ET
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
2021-06-25 12:30 ET
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
2021-06-11 15:49 ET
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
2021-06-09 01:03 ET
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
2021-06-08 20:37 ET
CEL-SCI Announces Bought Deal Offering
2021-05-18 13:00 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results
2021-02-16 14:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results
2021-01-08 13:30 ET
CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
2021-01-04 14:15 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-12-30 13:00 ET
CEL-SCI Reports Fiscal 2020 Financial Results and Clinical & Corporate Developments
2020-12-14 13:30 ET
CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference
2020-12-11 16:29 ET
CEL-SCI Announces the Closing of Its $14.65 Million Bought Deal
2020-12-08 23:44 ET
CEL-SCI Announces Bought Deal Offering
2020-12-07 14:15 ET
CEL-SCI Announces Update on Phase 3 Cancer Trial Results
2020-12-01 14:00 ET
CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies
2020-09-18 13:00 ET
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
2020-09-15 13:15 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-09-11 13:00 ET
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference
2020-08-31 13:00 ET
CEL-SCI Corporation to Present at The LD 500 Virtual Conference
2020-08-11 12:30 ET
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results
2020-07-24 12:30 ET
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment
2020-06-30 12:30 ET
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises
2020-06-24 14:00 ET
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series
2020-05-11 12:00 ET
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results
2020-05-04 11:15 ET
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer
2020-04-23 13:15 ET
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
2020-04-08 12:00 ET
Important Update For CEL-SCI Corporation Annual Meeting of Shareholders
2020-03-30 20:05 ET
CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders
2020-03-26 15:05 ET
CEL-SCI Announces the Closing of Its $7.7 Million Bought Deal
2020-03-24 13:25 ET
CEL-SCI Increases Previously Announced Bought Deal to $7.7 Million
2020-03-24 01:46 ET
CEL-SCI Announces Bought Deal Offering
2020-03-23 13:00 ET
CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology
2020-03-09 11:55 ET
CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection
2020-02-26 20:19 ET
CEL-SCI Corporation Issues Letter to Shareholders
2020-02-10 13:00 ET
CEL-SCI Corporation Reports First Quarter Fiscal 2020 Financial Results
2020-02-06 14:00 ET
CEL-SCI to Present at 2020 BIO CEO & Investor Conference
2020-01-10 13:30 ET
CEL-SCI to Participate in Upcoming Investor Conferences
2020-01-07 19:40 ET
CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp.
2019-12-27 16:15 ET
CEL-SCI Announces the Closing of Its $5.5 Million Underwritten Offering
2019-12-24 12:16 ET
CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock
2019-12-23 21:04 ET
CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock
2019-12-16 21:15 ET
CEL-SCI Reports Fiscal 2019 Financial Results and Clinical & Corporate Developments
2019-12-06 14:00 ET
CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

SEC forms

Show financial reports only

SEC form 10
2026-02-17 22:01 ET
CEL-SCI Corporation published news for 2025 q4
SEC form 10
2025-12-23 22:36 ET
CEL-SCI Corporation reported for 2025 q3
SEC form 8
2025-11-24 22:00 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-24 22:00 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-05 21:31 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-11-05 21:31 ET
CEL-SCI Corporation published news for 2025 q3
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-08-29 17:15 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 10
2025-08-14 13:31 ET
CEL-SCI Corporation reported for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-07-14 20:25 ET
CEL-SCI Corporation published news for 2025 q2
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 8
2025-05-23 20:16 ET
CEL-SCI Corporation published news for 2025 q1
SEC form 10
2025-05-14 20:20 ET
CEL-SCI Corporation reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
CEL-SCI Corporation reported for 2025 q1
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 8
2025-03-18 21:07 ET
CEL-SCI Corporation published news for 2024 q4
SEC form 10
2025-02-14 16:15 ET
CEL-SCI Corporation reported for 2024 q4
SEC form 10
2025-02-14 00:00 ET
CEL-SCI Corporation reported for 2024 q4
SEC form 10
2025-01-13 00:00 ET
CEL-SCI Corporation reported for 2024 q3
SEC form 10
2024-08-14 16:27 ET
CEL-SCI Corporation reported for 2024 q2
SEC form 10
2024-08-14 00:00 ET
CEL-SCI Corporation reported for 2024 q2
SEC form 10
2024-05-15 16:17 ET
CEL-SCI Corporation reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
CEL-SCI Corporation reported for 2024 q1
SEC form 10
2024-02-14 00:00 ET
CEL-SCI Corporation reported for 2023 q4
SEC form 10
2023-12-21 16:15 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-12-21 00:00 ET
CEL-SCI Corporation reported for 2023 q3
SEC form 10
2023-08-10 16:10 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
CEL-SCI Corporation reported for 2023 q2
SEC form 6
2023-07-20 16:10 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-18 16:05 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-14 12:25 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 6
2023-07-12 09:01 ET
CEL-SCI Corporation published news for 2023 q2
SEC form 10
2023-05-12 16:11 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
CEL-SCI Corporation reported for 2023 q1
SEC form 6
2023-05-02 16:39 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-05-01 16:15 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-19 10:56 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:01 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-04-10 10:00 ET
CEL-SCI Corporation published news for 2023 q1
SEC form 6
2023-03-09 10:09 ET
CEL-SCI Corporation published news for 2022 q4
SEC form 10
2023-02-14 16:16 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2023-02-14 00:00 ET
CEL-SCI Corporation reported for 2022 q4
SEC form 10
2022-12-27 16:15 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 10
2022-12-27 00:00 ET
CEL-SCI Corporation reported for 2022 q3
SEC form 6
2022-09-13 11:23 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-08-22 09:00 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 10
2022-08-12 16:17 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
CEL-SCI Corporation reported for 2022 q2
SEC form 6
2022-08-08 16:06 ET
CEL-SCI Corporation published news for 2022 q2
SEC form 6
2022-06-13 17:02 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-05-13 16:16 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 10
2022-05-13 00:00 ET
CEL-SCI Corporation reported for 2022 q1
SEC form 6
2022-04-29 16:08 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 6
2022-04-29 16:06 ET
CEL-SCI Corporation published news for 2022 q1
SEC form 10
2022-02-11 16:16 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2022-02-11 00:00 ET
CEL-SCI Corporation published news for 2021 q4
SEC form 10
2021-12-21 16:33 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-12-21 00:00 ET
CEL-SCI Corporation published news for 2021 q3
SEC form 10
2021-08-13 16:17 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 10
2021-08-13 00:00 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-07 15:24 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-07-01 17:43 ET
CEL-SCI Corporation published news for 2021 q2
SEC form 6
2021-06-29 08:29 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-06-09 16:09 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:02 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 6
2021-05-18 11:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 16:11 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
CEL-SCI Corporation published news for 2021 q1
SEC form 10
2021-02-12 16:16 ET
CEL-SCI Corporation published news for 2020 q4
SEC form 6
2020-12-30 17:36 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:17 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-30 17:16 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 10
2020-12-29 17:01 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-29 17:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-09 17:05 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-12-07 18:00 ET
CEL-SCI Corporation published news for 2020 q3
SEC form 6
2020-10-30 16:17 ET
CEL-SCI Corporation published news for 2020 q3